Mamelak M, Csima A, Price V
J Clin Pharmacol. 1984 Feb-Mar;24(2-3):65-75. doi: 10.1002/j.1552-4604.1984.tb02767.x.
The short- and intermediate-term actions, as well as the carryover and withdrawal effects, of quazepam , a new benzodiazepine hypnotic with a half-life of 60 to 100 hours, were compared with those of triazolam, a triazolodiazepine hypnotic with a half-line of 2 to 3 hours. Both the subjective effects of these drugs as well as their objective actions on the sleep EEG were sought. The study was conducted on two groups of six subjects with chronic insomnia who ranged in age from 32 to 56 years. Each subject was studied for 25 consecutive nights. Placebo was administered at bedtime on the first four nights, followed by 30 mg quazepam or 0.5 mg triazolam on the next 14 nights and by placebo again on the ensuing seven withdrawal nights. Both drugs increased the total sleep time during their administration and improved the subjective quality of sleep. Major differences, however, were observed on withdrawal. A significant and marked decrease in the total sleep time occurred with triazolam on the first withdrawal night. With quazepam , rebound insomnia was not observed at any time during the seven-day withdrawal period.
将半衰期为60至100小时的新型苯二氮䓬类催眠药夸西泮的短期和中期作用以及残留和撤药效应，与半衰期为2至3小时的三唑并二氮䓬类催眠药三唑仑进行了比较。研究了这些药物的主观效应及其对睡眠脑电图的客观作用。该研究针对两组年龄在32至56岁之间的慢性失眠受试者进行，每组六人。每位受试者连续接受25晚的研究。前四晚在睡前服用安慰剂，接下来的14晚服用30毫克夸西泮或0.5毫克三唑仑，随后的七个撤药夜晚再次服用安慰剂。两种药物在给药期间均增加了总睡眠时间，并改善了睡眠的主观质量。然而，在撤药时观察到了主要差异。三唑仑在撤药第一晚总睡眠时间出现显著且明显的减少。使用夸西泮时，在七天的撤药期内任何时候均未观察到反弹性失眠。
